INTRODUCTION {#s1}
============

Retinitis pigmentosa (RP) refers to a group of retinal dystrophies that is a major cause of visual disability worldwide, with a prevalence of ∼1 in 4000 for an estimated total of 1.5 million patients ([@MCS004952JAUC22]). The disease is caused in most cases by a primary degeneration of the rod photoreceptors followed by the cones, and thus is characterized as a rod--cone dystrophy ([@MCS004952JAUC4]; [@MCS004952JAUC5]; [@MCS004952JAUC22]). The typical course of the disease for patients is initial nyctalopia, followed by progressive constriction of the visual fields and "tunneling" of vision. Macular function is preserved until late stages of the disease. On clinical examination, fundus abnormalities include intraretinal bone spicule pigment migration, attenuation of the retina vessels, and waxy pallor of the optic nerve. Disease severity generally depends on the Mendelian mode of inheritance: X-linked RP (5%--15% of patients) has a more severe course of disease as compared to autosomal recessive RP (50%--60%), whereas autosomal dominant RP (30%--40%) is generally the mildest ([@MCS004952JAUC4]; [@MCS004952JAUC5]; [@MCS004952JAUC22]; [@MCS004952JAUC10]).

Leber congenital amaurosis (LCA) refers to a group of rod--cone dystrophies that present congenitally or within the first months of life with severe vision loss, nystagmus, and extinguished electroretinogram responses in most cases ([@MCS004952JAUC12]; [@MCS004952JAUC7]; [@MCS004952JAUC20]). LCA is inherited in an autosomal recessive manner, and ∼5%--10% of cases are caused by pathogenic variants in the gene retinal pigment epithelium (RPE)-specific protein 65 kDa (*RPE65*, OMIM: 180069) ([@MCS004952JAUC12]). This gene encodes for a retinol isomerase that serves as a vital component of the visual cycle by regenerating 11-*cis*-retinol from *all-trans*-retinyl ester ([@MCS004952JAUC21]). Recently, *RPE65*-LCA became the first retinal dystrophy to have Federal Drug Administration (FDA)-approved gene therapy after successful results from safety and efficacy studies ([@MCS004952JAUC19]).

In 2011, [@MCS004952JAUC1] reported the first study of the heterozygous *RPE65* p.D477G variant causing autosomal dominant RP (adRP) in two Irish families. Further reports have shown that RPE65-adRP can present with chorioretinal atrophy resembling choroideremia ([@MCS004952JAUC1]; [@MCS004952JAUC6]; [@MCS004952JAUC8]). Nonpenetrance and mild disease have also been reported ([@MCS004952JAUC1]; [@MCS004952JAUC6]). In this study, we describe a patient with the variant p.D477G in *RPE65* who presented with a novel phenotype that has not been previously associated with this variant.

RESULTS {#s2}
=======

A 57-yr-old male patient was referred to our office for a retinal evaluation. The patient reported a subjective decrease in visual acuity beginning ∼1 yr earlier with objects appearing "blurry" as well as decreased vision in low-light environments. Medical and ocular history were otherwise noncontributory. The patient\'s mother has a diagnosis of age-related macular degeneration, but there is no family history of vision problems similar to those of the patient.

On examination, best-corrected visual acuity (BCVA) was 20/50 bilaterally. Dilated fundus examination revealed widespread mottling of the RPE in the periphery, with more delineated areas of RPE atrophy centrally but with foveal sparing ([Fig. 1](#MCS004952JAUF1){ref-type="fig"}A,B). Short-wave autofluorescence (SW-AF) imaging supported the findings from fundus examination. Patchy hypoautofluorescence was observed throughout the posterior pole of both eyes. In the right eye, multiple areas of RPE atrophy were observed on the macula, whereas in the left eye, there was only one similar area ([Fig. 1](#MCS004952JAUF1){ref-type="fig"}C,D). The fovea was spared bilaterally. Spectral-domain optical coherence tomography (SD-OCT) scans revealed that in the areas of RPE atrophy, the ellipsoid zone (EZ) line and the underlying RPE and Bruch\'s membrane layers had degenerated, leading to a collapse of the overlying retinal layers ([Fig. 1](#MCS004952JAUF1){ref-type="fig"}E,F). Outer retinal tubulations were also appreciated in the areas of atrophy ([Fig. 1](#MCS004952JAUF1){ref-type="fig"}E). The retinal layers were conserved in the fovea. On full-field electroretinography (ff-ERG), the scotopic rod-specific responses were extinguished. Maximal responses exhibited a- and b-wave amplitudes of 87 µV and 74 µV in the right and 106 µV and 105 µV in the left eye. Photopic 30-Hz flicker amplitudes were diminished to 62 µV on the right and 48 µV on the left eye. Genetic testing via whole-exome sequencing (WES) revealed the variant c.1430A \> G (p.D477G) in the gene *RPE65*. No other additional variants were found.

![Clinical examination of the presented patient. Dilated fundus examination of the right eye (*A*) revealed widespread mottling of the retinal pigment epithelium (RPE) in the periphery. More delineated areas of RPE atrophy are observed centrally with the underlying white sclera visible. RPE mottling and atrophy is also observed in the left eye (*B*) but to a lesser degree as compared to the right eye. There is sparing of the fovea bilaterally. Short-wavelength fundus autofluorescence of the right (*C*) and left (*D*) eyes revealed patchy hypoautofluorescence throughout the posterior pole. In the right eye, multiple areas of deep hypoautofluorescence corresponding to RPE atrophy were observed surrounding the fovea, whereas on the left eye there was only one such area. Spectral-domain optical coherence tomography (SD-OCT) scans and concurrently registered infrared images of the right (*E*) and left (*F*) eyes revealed that these lacunae-like, hypoautofluorescence areas correspond to regions where the ellipsoid zone (EZ) line and the underlying RPE and Bruch\'s membrane layers had degenerated, leading to a collapse of the overlying retinal layers (the boundaries are marked by red lines on the infrared image and by red arrows on the SD-OCT scan). Outer retinal tubulations are also appreciated (yellow arrowhead), suggesting photoreceptor and outer retinal degeneration. Outside of these areas of RPE atrophy, the retinal layers are intact.](MCS004952Jau_F1){#MCS004952JAUF1}

DISCUSSION {#s3}
==========

The severe chorioretinal phenotype of *RPE65*-adRP caused exclusively by the D477G variant was first described in two Irish families in which the disease exhibited intrafamilial phenotypic variability ([@MCS004952JAUC1]). In contrast to severe disease with extensive chorioretinal atrophy, nonpenetrance, and mild disease with peripheral pigment migration were also observed in some individuals ([@MCS004952JAUC1]). Similarly, two different families in which both nonpenetrance and severe choroidal disease were observed have been reported ([@MCS004952JAUC6]). In addition, our group published a 2-yr follow-up study on a patient also afflicted with adRP caused by the same previously reported D477G variant in *RPE65* ([@MCS004952JAUC8]). Based on these studies, the severe chorioretinal phenotype associated with D477G *RPE65*-adRP can best be described as resembling choroideremia ([Fig. 2](#MCS004952JAUF2){ref-type="fig"}). On fundoscopy, extensive chorioretinal atrophy is observed throughout the posterior pole, whereas in SW-AF images, there is extensive loss of autofluorescence in the areas of RPE atrophy, with scalloped regions of preserved retina and RPE. Unlike choroideremia, however, disease onset appears in adulthood for most patients with *RPE65*-adRP.

![Clinical examinations of a patient with choroideremia and a patient with the classical phenotype of RPE65 autosomal dominant retinitis pigmentosa. Dilated fundus examination (*A*) and short-wavelength fundus autofluorescence (SW-AF) imaging (*B*) of a 20-yr-old patient with choroideremia caused by the mutation c.1584_1587del (p.V529Hfs\*7) in the gene *CHM*. Fundoscopy reveals chorioretinal atrophy, with the underlying white sclera visible on some areas of the posterior pole. On SW-AF, there is extensive loss of autofluorescence in the areas of RPE atrophy along with scalloped regions of preserved retina. The classically described phenotype of *RPE65*-autosomal dominant retinitis pigmentosa (adRP) resembles choroideremia. On dilated fundus examination (*C*) and SW-AF imaging (*D*) of a 69-yr-old patient with adRP caused by the mutation c.1430A \> G (p.D477G) in *RPE65*, chorioretinal atrophy and scalloped regions of preserved retina in SW-AF images can be appreciated, thus resembling the phenotype observed in choroideremia.](MCS004952Jau_F2){#MCS004952JAUF2}

The patient we report in this study presents with a novel phenotype that has not been previously attributed to *RPE65*-adRP. In our patient, we observed RPE mottling by fundoscopy and patchy hypoautofluorescence in SW-AF imaging instead of severe chorioretinal atrophy of the posterior pole. Furthermore, our patient exhibits macular lacunae--like lesions of severe RPE atrophy with foveal sparing. In the areas of atrophy, outer retinal tubulations are appreciated, suggesting photoreceptor and outer retinal degeneration ([@MCS004952JAUC23]). Phenotypes similar to our patient\'s have previously been reported in female carriers of choroideremia, suggesting that RPE65-adRP can resemble either choroideremia in males or the carrier choroideremia state in females ([@MCS004952JAUC3]; [@MCS004952JAUC9]). In conjunction with previous reports, our study serves to illustrate that there is phenotypic variability of the D477G variant causing *RPE65*-adRP. Variable expressivity and incomplete penetrance are more common with adRP, and this phenomenon occurs in other genes that cause adRP such as *PRPF8* and *PRPF31* ([@MCS004952JAUC4]; [@MCS004952JAUC14]; [@MCS004952JAUC18]).

The mechanism of pathogenicity of the D477G mutation has been explored by multiple studies. Initially, [@MCS004952JAUC1] proposed that the variant might destabilize folding of the tertiary RPE65 protein structure. A later study by Shin et al. used mutant knock-in mice and showed that D477G acts as a dominant negative mutation of *RPE65* and causes a delay in the chromophore regeneration of the visual cycle ([@MCS004952JAUC21]). Choi et al. later demonstrated that the amino acid substitution is a toxic gain-of-function mutation, rather than a disturbance to protein folding or tertiary structure ([@MCS004952JAUC2]). Nevertheless, the most recent study on the mechanism of *RPE65*-adRP reported that D477G causes aberrant RNA splicing to create the pathogenic effect in humans and does not result in a gain-of-function mutation ([@MCS004952JAUC13]). Similar to D477G *RPE65-*adRP, other genes that are known to cause variable expressivity and incomplete penetrance are also involved in RNA processing, such as *PRPF8* and *PRPF31* ([@MCS004952JAUC14]; [@MCS004952JAUC18]). The variable expressivity of the D477G mutation, including nonpenetrance in some carriers, suggests that there might be additional mutations or modifier effects by other genes. Therefore, it is integral to perform further genomic analysis to help elucidate possible linkage of multiple genes involved in the pathogenicity of this mutation.

In conclusion, this study expands the currently known phenotypic presentations of adRP caused by the D477G mutation in *RPE65*. This study also serves to increase awareness of the variable phenotypic presentations of *RPE65*-retinopathy. In patients in which phenotypic presentation suggests choroideremia or a choroideremia carrier state but targeted sequencing of the gene *CHM* is negative, sequencing of *RPE65* should be pursued.

METHODS {#s4}
=======

Subjects and Ophthalmic Evaluation {#s4a}
----------------------------------

Ophthalmic evaluation of the patient included measurement of best corrected visual acuity, pupillary dilation (\>7 mm) followed by fundus examination, photography, SD-OCT, and SW-AF (488 nm). ff-ERG was performed using DTL recording electrodes and Ganzfeld stimulation according to the standards from the International Society for Clinical Electrophysiology of Vision (ISCEV) ([@MCS004952JAUC15],[@MCS004952JAUC16]).

DNA Analysis {#s4b}
------------

DNA was obtained from the patient\'s peripheral blood to perform clinical WES. WES was performed using SureSelectXT Human All Exon V5 + UTRs (Agilent Technologies) capture and HiSeq2500 (Illumina) sequencing technology. Sequence reads obtained were analyzed for the presence of pathogenic mutations by alignment to the human genome reference sequence (GRCh37/hg19) using the NextGENe software (Softgenetics) and our own analytical pipeline at the Laboratory of Personalized Genomic Medicine at Columbia University ([@MCS004952JAUC17]). Identified variants were assessed for clinical phenotypic match and classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines for the interpretation of sequence variants ([@MCS004952JAUC11]). Variant information is provided in [Table 1](#MCS004952JAUTB1){ref-type="table"}; sequencing coverage data is provided in [Table 2](#MCS004952JAUTB2){ref-type="table"}.

###### 

Variant table for the *RPE65* c.1430A \> G (p.Asp477Gly) variant

  Gene                   Chromosome               HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect   dbSNP/dbVar ID     Genotype
  --------- ------------------------------------ -------------------- ------------------------ -------------- ------------------ ---------------- --------------
  *RPE65*    Chr 1:68896768T \> C (GRCh37/hg19)      c.1430A \> G           p.Asp477Gly           Missense       Substitution     Not available    Heterozygous

###### 

Whole-exome sequencing coverage table for the *RPE65* c.1430A \> G (p.Asp477Gly) variant

  Sample    Percentage of reads aligned   Average read coverage   Percentage of *RPE65* sites (2605 bases) with ≥10× coverage
  --------- ----------------------------- ----------------------- -------------------------------------------------------------
  Proband   97.28%                        146.72                  100

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Whole-exome sequencing data is not publicly available as our patient consent does not permit the data to be uploaded to a depository. Patient consent could not be obtained. The NM_000329.3(RPE65):c.1430A \> G (p.D477G) variant can be accessed through OMIM Allelic Variant 180069.0013.
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